HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $8 price target.
Stocks · News reference
Gain Therapeutics Issues CEO Letter; Expects To Fund Operations Into Q2 2027, Based On Current Operating Plans, Including Completion Of Phase 1B Open-Label Extension In October And Initiation Of A Phase 2 During Q3 2026
To our valued Shareholders,As we progress through 2026 and look ahead to delivering continued significant progress, I want to thank you for your steadfast support of Gain Therapeutics. The year has been one of
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Gain Therapeutics Announces Poster Presentation At International Congress Of Parkinson’s Disease And Movement Disorders, October 4-8; MDS-UPDRS Motor Scores Demonstrated Stability To Baseline Recorded At Study Entry With No Disease Progression Among The 12 Evaluable Participants; Results Support Disease-Modifying Potential Of Rexaceract
Gain Therapeutics Plans To Initiate Phase 2 Rexaceract Trial In Q1 Next Year
8-K filing — Gain Therapeutics, Inc. (GANX)
Filed: 2026-10-01 AccNo: 0001104659-26-112624 Size: 203 KB Item 8.01: Other Events